MMI-0100 是一种细胞渗透性肽抑制剂,抑制丝裂原活化蛋白激酶活化蛋白激酶 II (MK2)。MMI-0100 在体内外减少内膜增生。MMI-0100 抑制 IL-6 表达而不影响 IL-8 表达。MMI-0100 抑制纤维化过程,例如静脉移植疾病。
生物活性 | MMI-0100 is a cell-permeant peptide inhibitor of mitogen activated protein kinase activated protein kinase II (MK2). MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. MMI-0100 suppressesIL-6expression without effect onIL-8expression. MMI-0100 suppresses fibrotic processes such as vein graft disease[1]. |
体外研究 (In Vitro) | Naphthofluorescein (compound 19) (0-10 μM; 24 hours) suppresses the HIF-1 reporter activity in a concentration-dependent manner.[1]. MMI-0100 (0.25 and 0.5 mM; 24 hours) slightly increases cell proliferation in both cell types compared to control cells treated with 20 ng/ml TNF-α alone[1]. MMI-0100 (1 mM) treatment also increases both EC (11%) and SMC (7%) proliferation as compared to control, this response is not as robust as that induced by treatment with 0.5 mM MMI-0100[1]. MMI-0100 does not induce EC apoptosis at any dose[1].
Cell Viability Assay[1] Cell Line: | human endothelial cell (EC) and smooth muscle cell (SMC) | Concentration: | 0.25, 0.5, and 1 mM | Incubation Time: | 24 hours | Result: | Slightly increased cell proliferation in both cell types compared to control cells. |
|
体内研究 (In Vivo) | MMI-0100 (100 μM; 28 days) inhibits intimal hyperplasia in a mouse vein graft model[1].
Animal Model: | 12-week-old C57Bl/6 wild type mice (intimal hyperplasia)[1] | Dosage: | 100 μM | Administration: | vein graft, 28 days | Result: | Diminished wall thickness at all postoperative time points in vein grafts treated with MMI-0100, with a ratio of 2.6-fold thicker at 4 weeks, compared to 4.7-fold thicker at 4 weeks in control grafts. |
|
Clinical Trial | |
分子量 | |
性状 | |
Formula | |
CAS 号 | |
Sequence Shortening | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Sealed storage, away from moisture and light, under nitrogen Powder | -80°C | 2 years | | -20°C | 1 year |
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen) |
溶解性数据 | In Vitro: H2O : 100 mg/mL(43.79 mM;Need ultrasonic) 配制储备液 1 mM | 0.4379 mL | 2.1895 mL | 4.3790 mL | 5 mM | 0.0876 mL | 0.4379 mL | 0.8758 mL | 10 mM | 0.0438 mL | 0.2189 mL | 0.4379 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture and light, under nitrogen)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: PBS Solubility: 14.29 mg/mL (6.26 mM); Clear solution; Need ultrasonic
*以上所有助溶剂都可在本网站选购。 |